Immunogenicity and reactogenicity associated with an 18-month booster dose of a new diphtheriatetanus-whole cell pertussis vaccine

Journal of Paediatrics and Child Health

Volumn 34, Issue 4, 1998, Pages 346-348

  Nolan, T ^a,b   Hogg, G ^b   Darcy, M A ^a   Carlin, J B ^a   Skeljo, M ^c   Varigos, J ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c CSL LIMITED   (Australia)

Author keywords

Booster; Diphtheria; DTP; Immunisation; Pertussis; Tetanus

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; EMLA; TRIPLE ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DIPHTHERIA; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; TETANUS; VACCINATION;

EID: 0031880011     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1754.1998.00242.x     Document Type: Article

References (13)

1. W (diphtheria-tetanus-whole cell pertussis) vaccine. J. Paediatrics Child Health 1997; 33: 413-7.
2. Feery BJ. Incidence and type of reactions to triple antigen (DTP) and DT (CDT) vaccines. Med. J. Australia 1982; 2: 511-5.
3. th edn. National Health and Medical Research Council, Australian Government Publishing Service, Canberra, ACT, 1997.
4. Stewart A, Nolan TM, HoggG, McEwen J. Serosurvey of antibodies to diphtheria, tetanus and pertussis in infants before and after immunisation with DTP (triple antigen) vaccine. J. Paediatrics Child Health 1996; 32: 378-81.
5. Lewis K, Cherry JD, Holroyd HJ, Baker LR, Dudenhoeffer FE, Robinson RG. A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussiscomponent vaccine in 18-month-old children. Am. J. Dis Child 1986; 140: 872-6.
6. Auerbach BS, Wilson ME, Deforest A, Steinhoff M, Halsey, N. Dose-response to acellular pertussis vaccine and comparison with whole cell pertussis vaccine at 15-24 months and 4-6 years of age. Vaccine 1992; 10: 14-20.
7. Englund JA, Glezen WP, Barreto L. Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J. Infect. Dis. 1992; 166: 1436-41.
8. Feldman S, Perry CS, Andrew M et al. Comparison of acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month children. J. Pediatr. 1992; 121: 857-61.
9. Englund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL. Acellular and whole-cell pertussis vaccines as booster doses: a multicentre study. Pediatrics 1994; 93: 37-43.
10. Halperin SA, Barreto L, Friesen, B, Meekison W. Immunogencitity of a five-component acellular vaccine in infants and young children. Arch. Pediatr. Adolesc. Med. 1994; 148: 495-502.
11. Blumberg DA, Mink CM, Cherry JD et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. J. Pediatr. 1991; 119: 194-204.
12. Report of the Pertussis Working Party. National Health and Medical Research Council, National Health and Medical Research Council, Australian Government Publishing Service, Canberra, ACT, 1997.
13. Marwick C. Acellular pertussis vaccine is licensed for infants. JAMA 1996; 276: 516-7.